<DOC>
	<DOCNO>NCT02418559</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetics JNJ-63623872 follow oral administration single ascend dose JNJ-63623872 healthy Japanese adult participant .</brief_summary>
	<brief_title>A Study Investigate Safety , Tolerability , Pharmacokinetics JNJ-63623872 Healthy Japanese Adult Participants</brief_title>
	<detailed_description>This double-blind ( test experiment neither person give treatment patient know treatment patient receiving ) , placebo-controlled , randomize ( study medication assign participant chance ) single-center study JNJ-63623872 . The duration study approximately 5.5 week ISO per participant . The study consist 3 part : Screening Phase ( 28 day study commences Day 1 ) ; double-blind Treatment Phase ( single oral dose JNJ-63623872 placebo Day 1 fast condition ) ; Follow Phase ( 7-10 day study drug administration ) . All eligible participant randomly assign 1 3 group . The planned dos escalate stepwise fashion safety tolerability precede dose find acceptable . Participants Group 1 receive JNJ-63623872 300 milligram ( mg ) placebo , Group 2 receive JNJ-63623872 600 mg placebo Group 3 receive JNJ-63623872 1200 mg placebo . Study drug administer follow 10-hour overnight fast . Blood sample collect evaluation pharmacokinetics pre-dose post-dose study treatment . Pharmacokinetics JNJ-63623872 evaluate primarily . Participants ' safety monitor throughout study .</detailed_description>
	<criteria>Be Japanese participant reside outside Japan 5 year whose parent grandparents Japanese determine participant 's verbal report Each participant must sign Informed Consent Form ( ICF ) indicate understands purpose procedure require study willing participate study Participant must willing able adhere prohibition restriction specify protocol A female participant must either : 1 . Not childbearing potential : postmenopausal [ great ( &gt; ) 45 year age amenorrhea least 2 year , age amenorrhea least 6 month serum follicle stimulate hormone ( FSH ) level &gt; 40 International Units ( IU ) / liter ( L ) ( confirm Screening postmonopausal woman ) ] OR 2 . Permanently sterilize ( eg , bilateral tubal occlusion [ include tubal ligation procedure consistent local regulation ] , hysterectomy , bilateral salpingectomy , bilateral oophorectomy ) otherwise incapable become pregnant , OR c. If childbearing potential heterosexually active , practice effective method birth control entry agree continue use two effective method contraception throughout study least 30 day receive study drug A male participant sexually active woman childbearing potential must agree use two effective method birth control 30 day receive study drug , male participant must also donate sperm study 3 month receive study drug Participant history current clinically significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder ( include abnormal bleeding blood dyscrasia ) , lipid abnormality , significant pulmonary disease , include bronchospastic respiratory disease , diabetes mellitus , hepatic renal insufficiency , thyroid disease , neurologic psychiatric disease , infection , illness Investigator considers exclude participant could interfere interpretation study result Participant past history heart arrhythmia ( extrasystoli , tachycardia rest ) , history risk factor Torsade de Pointes syndrome ( eg , hypokalemia , family history long QT Syndrome ) Participants history clinically significant skin disease , limited , dermatitis , eczema , drug rash , psoriasis , food allergy , urticaria Participants history clinically significant drug allergy , limited , sulfonamides penicillin , drug allergy diagnose previous study experimental drug Participant take disallowed therapy note protocol , Prestudy Concomitant Therapy plan study drug</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Healthy</keyword>
	<keyword>JNJ-63623872</keyword>
	<keyword>Japanese Adult Participants</keyword>
</DOC>